首页 因塞特(usINCY)-基本信息

因塞特(usINCY)-基本信息

日报更新时间:04-10 10:00

周报更新时间:04-11 03:39

行情信息

今开价:80.635

最高价:80.75

成交量:1198471.0

昨收价:79.96

最低价:78.44

最新价:79.87

行情图标
概要信息

中文名称:因塞特


英文名称:Incyte


行业:医疗


简介:因塞特医疗公司是一家生物制药公司,主要从事发现、开发和商业化拥有所有权的小分子药物,以应对严重未满足的医疗需要


电话:1-302-4986700


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

因塞特医疗(英赛德公司)开发主治HIV、癌症与炎症疾病药物发现,从事基因资讯提供,并结合基因资料与强大的软体工具,使研究人员可以分析比较来自有机活体的数百万种基因组合,加速开发新的疗法。因塞特医疗Incyte Corporation(INCY)产品百科: JAKAFI——治疗骨髓纤维化和真性红细胞增多癌症,商用阶段,因塞特医疗公司通过专业药店网络以及批发销售其JAKAFI产品。 Ruxolitinib Cream——用于斑秃的治疗,目前处于II期临床试验阶段。 INCB52793——用于治疗晚期恶性肿瘤,目前处于I/II期临床试验阶段。 Baricitinib——处于类风湿关节炎治疗的III期临床试验阶段;同时处于牛皮癣和糖尿病肾病的II期临床试验阶段;同时处于特应性皮炎治疗的II期临床试验阶段。 INCB39110——与osimertinib结合治疗肺癌,目前处于I/II期临床试验阶段;与pembrolizumab结合治疗晚期恶性肿瘤,目前也处于I/II期临床试验阶段;同时处于移植物抗宿主病治疗的II期临床试验阶段。 Epacadostat——用于多种肿瘤治疗,目前处于II期临床试验阶段;处于治疗非小细胞肺癌以及晚期黑色素瘤的I/II期临床试验阶段。 INCB54329 (BRD) and INCB53914 (PIM)——治疗晚期恶性肿瘤的I/II期临床试验阶段。 INCB50465 (PI3Kd)——治疗B-细胞恶性肿瘤和实体瘤的I/II期临床试验阶段。 INCB54828 (FGFR) and INCSHR1210——处于实体瘤治疗的I/II期临床试验阶段。 Capmatinib——处于治疗非小细胞肺癌、胶质细胞瘤和肝癌的II期临床试验阶段。因塞特医疗(Incyte Corporation)与诺华公司(Novartis International Pharmaceutical Ltd.)、礼来公司(Eli Lilly and Company)、安帝君斯(Agenus Inc.)、辉瑞制药(Pfizer Inc.)、Merus N.V.、Calithera Biosciences, Inc.、中国江苏恒瑞医药股份有限公司(Jiangsu Hengrui Medicine Co., Ltd.)以及Abramson Cancer Center签订了合作协议。 2015年9月,因塞特医疗宣布以7.95亿美金获得江苏恒瑞医药股份有限公司(SH:600276)的PD-1单克隆抗体(SHR-1210)的独家开发和商业化权利。 Novartis 收购了Incyte的c-Met 抑制剂—— capmatinib (INC280, INCB028060)。 2017年4月16日,由于安全性和剂量原因,FDA拒绝了因塞特医疗每日一次的类风湿关节炎药物巴利西肽(baricitinib),指示公司股价暴跌超过10%。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-16 Flannelly Barry P Officer Sell 959 79.91
2019-07-14 Swain (Paula J) Officer Sell 2500 80.00
2019-07-14 Swain (Paula J) Officer Sell 639 81.39
2019-07-14 Swain (Paula J) Officer Buy 2500 64.55
2019-07-14 Trower (Paul) Officer Sell 291 81.39
2019-07-14 Hoppenot Herve Chief Executive Officer Sell 2400 81.39
2019-07-14 Yao (Wenqing) Officer Sell 639 81.39
2019-07-14 Flannelly Barry P Officer Sell 430 81.39
2019-07-14 Stein (Steven H.) Officer Sell 409 81.39
2019-07-04 Trower (Paul) Officer Sell 148 85.28
2019-07-04 Swain (Paula J) Officer Sell 404 85.28
2019-07-04 Yao (Wenqing) Officer Sell 404 85.28
2019-07-04 Stein (Steven H.) Officer Sell 267 85.28
2019-07-04 Flannelly Barry P Officer Sell 273 85.28
2019-07-04 Iyengar (Vijay K) Officer Sell 273 85.28
2019-07-04 Hoppenot Herve Chief Executive Officer Sell 1552 85.28
2019-07-01 Stein (Steven H.) Officer Buy 6761 --
2019-07-01 Yao (Wenqing) Officer Sell 619 85.01
2019-07-01 Flannelly Barry P Officer Buy 6761 --
2019-07-01 Hoppenot Herve Chief Executive Officer Buy 39648 --
2019-07-01 Swain (Paula J) Officer Sell 619 85.01
2019-07-01 Hoppenot Herve Chief Executive Officer Sell 2410 85.01
2019-07-01 Pasquale (Maria E) General Counsel Sell 470 85.01
2019-07-01 Pasquale (Maria E) General Counsel Buy 6761 --
2019-07-01 Yao (Wenqing) Officer Buy 6761 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Goldman Sachs Group Inc 2335755 1.09% 723608 44.88% 2019-03-31
T. Rowe Price Associates, Inc. 7658026 3.57% -1148084 -13.04% 2019-03-31
Capital Research & Mgmt Co - Division 3 7801907 3.64% 163505 2.14% 2019-03-31
State Street Corporation 8118520 3.79% 495760 6.50% 2019-03-31
Capital Research and Management Company 9369616 4.36% -1365678 -12.72% 2019-07-31
Wellington Management Company LLP 15081000 7.03% -533825 -3.42% 2019-03-31
BlackRock Inc 15453453 7.21% 190491 1.25% 2019-03-31
Vanguard Group Inc 19135086 8.92% 316847 1.68% 2019-03-31
Baker Bros Advisors LP 34271827 15.98% 20220 0.06% 2019-03-31
BlackRock Fund Advisors 6466667 3.01% 19522 0.30% 2019-07-31
Vanguard Investments Australia Ltd 5095522 2.37% 30765 0.61% 2019-07-31
Sands Capital Management, LLC 4340795 2.02% -23600 -0.54% 2019-03-31
Geode Capital Management, LLC 2508013 1.17% -2213199 -46.88% 2019-03-31
Invesco Capital Management LLC 2728975 1.27% -168973 -5.83% 2019-07-31
State Street Global Advisors 2974086 1.38% 9480 0.32% 2019-07-31
BB Biotech AG 3620000 1.69% -188322 -4.95% 2019-03-31
Bellevue Asset Management AG 3652650 1.70% -40000 -1.08% 2019-07-31
Matrix Capital Management Company, LLC 4011847 1.87% -5000 -0.12% 2019-03-31
UBS Asset Mgmt Americas Inc 4038766 1.88% -186868 -4.42% 2019-03-31
Dodge & Cox 4255350 1.98% 15250 0.36% 2019-03-31
Amvescap Plc. 3078281 1.44% -36902 -1.18% 2018-12-31
BlackRock Asset Management Canada Ltd 5588786 2.61% 7572 0.14% 2019-05-31
BlackRock Japan Co Ltd 2603514 1.21% 2603514 -- 2019-04-30
Manning & Napier Group, LLC 2324273 1.09% -2291216 -49.64% 2018-12-31
SSGA Funds Management Inc 2048572 0.96% 43949 2.19% 2018-11-30
UBS Group AG 4561003 2.14% 4348199 2043.29% 2018-06-30
BlackRock Institutional Trust Company NA 4259711 2.00% -420056 -8.98% 2018-06-30
UBS Securities LLC 4561003 2.14% 4348199 2043.29% 2018-06-30
State Street Corp 7494341 3.53% 92337 1.25% 2018-06-30
State Street Global Advisors (Aus) Ltd 2028110 0.95% 48568 2.45% 2018-09-12
Invesco PowerShares Capital Mgmt LLC 2487199 1.17% 783356 45.98% 2018-06-30
Northern Trust Investments N A 1933597 0.91% 64282 3.44% 2018-06-30
Citadel Advisors Llc 1887200 0.89% 1264002 202.83% 2018-06-30
Pictet Asset Management SA 1815728 0.85% 418444 29.95% 2018-06-30
Goldman, Sachs & Co. 1338340 0.63% -466003 -25.83% 2018-06-30
Capital World Investors 5073600 2.39% -1043824 -17.06% 2018-03-31
Franklin Advisers Inc 1520631 0.72% -1102094 -42.02% 2018-03-31
J.P. Morgan Investment Management Inc 1675688 0.79% -37784 -2.21% 2018-03-31
Fidelity Management and Research Company 2203453 1.04% 222032 11.21% 2018-03-31
NORGES BANK 2283505 1.08% 679491 42.36% 2017-12-31
Orbimed Advisors, LLC 1476000 0.70% -187400 -11.27% 2017-09-30
Vanguard Specialized Funds 9466973 4.48% -2168935 -18.64% 2017-12-31
Jennison Associates LLC 1633173 0.77% 319191 24.29% 2017-09-30
Invesco Advisers, Inc 1414006 0.69% 5391 0.38% 2017-06-30
Brown Capital Management, LLC 2647505 1.41% -7324 -0.28% 2016-09-30
Capital Guardian Trust Company 1936960 1.03% -58006 -2.91% 2016-09-30
Columbia Mangmt Investment Advisers, LLC 1335459 0.71% 12786 0.97% 2016-09-30
American Century Inv Mgt Inc 1262158 0.67% 104343 9.01% 2016-09-30
BlackRock,Inc. 8940287 4.00% 793808083 -- 1999-11-30
The Vanguard Group 9223856 4.00% 818986174 -- 1999-11-30
Vanguard Specialized FundsVanguard Health Care Fund 10174343 4.00% 903379915 0.10% 1999-11-30
Julian C. Baker 14952708 4.00% 1327650943 0.10% 1999-11-30
Wellington Management GroupLLP 17035043 4.00% 1512541468 0.10% 1999-11-30
T. Rowe Price Associates,Inc. 20152359 4.00% 1789327956 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity 1183685 0.55% -- -- 2019-06-30
Vanguard Health Care Fund 11113220 5.17% -- -- 2019-03-31
American Funds New Perspective Fund 5108900 2.38% -63728 -1.23% 2019-06-30
Vanguard Total Stock Market Index Fund 5018653 2.33% 30752 0.62% 2019-06-30
Vanguard Mid-Cap Index Fund 4440147 2.06% 70080 1.60% 2019-06-30
Vanguard 500 Index Fund 3503609 1.63% 44572 1.29% 2019-06-30
UBS: Global Equity-UBS 3037802 1.41% -- -- 2019-03-31
iShares Nasdaq Biotechnology ETF 2116848 0.98% 22032 1.05% 2019-07-30
Dodge & Cox Stock Fund 1995900 0.93% -- -- 2019-06-30
SPDR 1979996 0.92% 1819 0.09% 2019-07-31
Invesco QQQ Trust 1925969 0.90% 1701 0.09% 2019-07-31
First Trust NYSE Arca Biotech Fund 1183896 0.55% -2853 -0.24% 2019-07-31
Vanguard Growth Index Fund 1302449 0.61% 46011 3.66% 2019-06-30
iShares Core S&P 500 ETF 1311968 0.61% -648 -0.05% 2019-07-30
American Funds IS 1330900 0.62% -- -- 2019-06-30
T. Rowe Price Health Sciences Fund 1477454 0.69% -103100 -6.52% 2019-06-30
Vanguard Institutional Index Fund 1661858 0.77% -8532 -0.51% 2019-06-30
T. Rowe Price Mid-Cap Growth Fund 1800000 0.84% -- -- 2019-06-30
Health Care Select Sector SPDR 941032 0.44% -4522 -0.48% 2019-06-28
Vanguard Mid-Cap Growth Index Fund 1112645 0.52% 7972 0.72% 2019-05-31
iShares Core S&P US Total Market ETF 1316121 0.61% 1188 0.09% 2019-05-30
iShares S&P 500 ETF 1316121 0.61% 1188 0.09% 2019-05-30
iShares Core S&P 500 ETF (CAD-Hedged) 1316121 0.61% 1188 0.09% 2019-05-30
iShares Core MSCI Kokusai ETF 1316121 0.61% 1188 0.09% 2019-05-30
iShares MSCI World ETF 1301757 0.61% -2700 -0.21% 2019-04-25
T. Rowe Price Mid-Cap Value Fund 1198500 0.56% 225500 23.18% 2018-12-31
VA CollegeAmerica New Perspective Fd 5394600 2.52% -- -- 2018-12-31
OH Putnam Fidelity Spartan 500 Index 1323237 0.62% 38286 2.98% 2019-01-31
Oppenheimer Global Fund 933760 0.44% -- -- 2018-11-30
American Funds Capital World Gr&Inc Fd 1761800 0.83% 114200 6.93% 2018-06-30
T. Rowe Price Growth Stock Fund 2715600 1.28% -160700 -5.59% 2018-03-31
VA CollegeAmerica Capital Wld Gr & Inc 1761800 0.83% 114200 6.93% 2018-06-30
VA CollegeAmerica Cap World G/I 529E 1761800 0.83% 114200 6.93% 2018-06-30
T. Rowe Price Mid-Cap Value 866400 0.41% 866400 -- 2018-06-30
Vanguard Health Care Inv 10657473 5.02% 1190500 12.58% 2018-06-30
VA CollegeAmerica New Perspective 529E 4885500 2.30% -1500200 -23.49% 2018-06-30
Vanguard Total Stock Mkt Idx 4526365 2.13% 18404 0.41% 2018-07-31
Vanguard Mid Cap Index I 4276142 2.01% 33605 0.79% 2018-07-31
Vanguard 500 Index Inv 3186958 1.50% 4645 0.15% 2018-07-31
T. Rowe Price Health Sciences 2421428 1.14% 149000 6.56% 2018-06-30
iShares Nasdaq Biotechnology 2404836 1.02% -4578 -0.19% 2018-09-12
T. Rowe Price Mid-Cap Growth 2000000 0.94% 750000 60.00% 2018-06-30
PowerShares QQQ ETF 1736689 0.75% -6720 -0.39% 2018-09-13
Vanguard Institutional Index I 1700559 0.80% 743 0.04% 2018-07-31
American Funds NVIT Growth-Income II 1330900 0.63% -- -- 2018-06-30
Vanguard Growth Index Inv 1269020 0.60% -3540 -0.28% 2018-07-31
Fidelity Spartan 1171933 0.55% 13823 1.19% 2018-07-31
Vanguard Mid-Cap Growth ETF 1094353 0.51% 4495 0.41% 2018-07-31
First Trust NYSE Arca Biotech ETF 1073678 0.46% -- -- 2018-09-13
T. Rowe Price Instl Large Cap Growth 734970 0.35% -- -- 2018-03-31
T. Rowe Price Growth Stock 2715600 1.28% -160700 -5.59% 2018-03-31
T. Rowe Price New Horizons 998597 0.47% -35700 -3.45% 2018-03-31
VA CollegeAmerica Grth Fund of Amer 529F 916000 0.43% -- -- 2018-03-31
American Funds NVIT Asset Allocation II 764450 0.36% -- -- 2018-03-31
VA CollegeAmerica Smcap World 529E 1088122 0.52% -- -- 2017-12-31
American Funds NVIT Growth II 1040000 0.49% -- -- 2017-09-30
Brown Capital Mgmt Small Co Inv 1233990 0.66% -- -- 2017-01-31
Vanguard Extended Market Idx Inv 2075367 1.10% 67078 3.34% 2016-12-31
American Funds NVIT Growth 3917500 2.10% -757500 -16.20% 2015-09-30
VA CollegeAmerica New Perspective 3836800 2.10% -- -- 2015-09-30
Fidelity® Select Biotechnology Portfolio 3833164 2.10% 236750 6.60% 2015-10-31
VA CollegeAmerica Growth Fund of America 3333000 1.80% -512100 -13.30% 2015-09-30
T. Rowe Price New Horizons Fund 1969300 1.10% -171200 -8.00% 2015-09-30
VA CollegeAmerica Small Cap World 4054883 2.20% -150117 -3.60% 2015-09-30
Vanguard Extended Market Index Fund 1690798 0.90% 22125 1.30% 2015-10-31

Julian Charles Baker Mr. Julian C. Baker is a Lead Independent Director at Genomic Health, Inc., Incyte Corp., a Co-Managing Member at Baker Bros. Advisors LP, a Managing Member at Baker Bros. Advisors GP LLC and a Partner at FBB Associates. He is on the Board of Directors at ACADIA Pharmaceuticals, Inc., Genomic Health, Inc. and Incyte Corp. Mr. Baker was previously employed as an Independent Director by Idera Pharmaceuticals, Inc., a Member by Credit Suisse First Boston Corp., a Principal by CSFB Private Equity Partners LLC, and an Advisory Board Member by Elm Street Venture Advisors, Inc. He also served on the board at Trimeris, Inc., Neurogen Corp., Theravance, Inc. and Presidio Pharmaceuticals, Inc. He received his undergraduate degree from Harvard University.
Wendy L. Dixon Wendy L. Dixon is Chairman at Sesen Bio, Inc. and President for Great Meadow Consulting LLC. She is also on the board of 5 other companies. In the past she held the position of Principal at West Pharmaceutical Services, Inc., Senior Vice President & President-Marketing at Merck & Co., Inc., Chief Marketing Officer for Bristol-Myers Squibb Co., Principal at Centocor, Inc., Senior Advisor at The Monitor Group, Inc., Principal at Osteotech, Inc. and Principal at Smithkline & French Laboratories US, Inc. Wendy L. Dixon received a graduate degree, a doctorate and an undergraduate degree from the University of Cambridge.
Christiana Stamoulis Presently, Christiana Stamoulis is Chief Financial Officer & Executive Vice President of Incyte Corp. She is also on the board of Hologic, Inc. In her past career she held the position of President & Chief Financial Officer of Unum Therapeutics, Inc., Managing Director-Investment Banking Division at Citigroup, Inc., Senior VP-Strategy & Business Development at Vertex Pharmaceuticals, Inc. and Vice President for Goldman Sachs & Co. LLC. Ms. Stamoulis received an undergraduate degree from Massachusetts Institute of Technology and an MBA from MIT Sloan School of Management.
Barry P. Flannelly Barry P. Flannelly is on the board of Genomic Health, Inc. and Executive Vice President & General Manager at Incyte Corp. In the past he held the position of Chief Executive Officer at OSS Healthcare, Inc., Vice President of Nektar Therapeutics and Senior Vice President-Commercial at Onyx Pharmaceuticals, Inc. Dr. Flannelly received a doctorate from the University of Maryland School of Pharmacy, an MBA from the University of Baltimore and an undergraduate degree from Massachusetts College of Pharmacy & Health Science.
Jean-Jacques Bienaim�0�1�0�8 Jean-Jacques Bienaim�0�1�0�8 holds the position of Chairman & Chief Executive Officer of BioMarin Pharmaceutical, Inc. He is also on the board of Incyte Corp., Biotechnology Innovation Organization and Pharmaceutical Research & Manufacturers of America. In the past he occupied the position of Lead Independent Director at NeurogesX, Inc., President & Chief Executive Officer at SangStat Medical Corp., Chairman, President & Chief Executive Officer at Genencor International, Inc., Director-Cardiopulmonary Products Marketing at Genentech, Inc. and Vice President & General Manager at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Jean-Jacques Bienaim�0�1�0�8 received an undergraduate degree from ESCP Europe Campus Paris, an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from The University of Texas.
David W. Gryska Currently, David W. Gryska is Chief Financial Officer & Executive Vice President of Incyte Corp. He is also on the board of Seattle Genetics, Inc., Aerie Pharmaceuticals, Inc. and PDL BioPharma, Inc. In his past career Mr. Gryska occupied the position of President, CEO, COO & Director at Myrexis, Inc., Chief Financial Officer & Senior Vice President for Celgene Corp., Principal at Strategic Consulting Group, Inc., Chief Financial Officer & Vice President for Cardiac Pathways Corp., Chief Financial Officer & Senior Vice President at Scios, Inc. and Partner at Ernst & Young LLP. He received an undergraduate degree from Loyola University of Chicago and an MBA from Golden Gate University.
Paul Alan Brooke Mr. Paul A. Brooke is Co-Founder & Managing Partner at venBio Partners LLC, Independent Director at Incyte Corp., Managing Member at PMSV Holdings LLC, Principal at Cheyne Capital LLC, Investment Advisor at Barrett, Vernon, Montgomery LLC, Senior Advisor at Morgan Stanley & Co. LLC, and Partner at venBio Select Advisor LLC. He is on the Board of Directors at Cytos Biotechnology AG, Incyte Corp., HoustonPharma, Inc., and LifeSync Holdings, Inc. Mr. Brooke was previously employed as Chairman by Alsius Corp. and Alsius Corp., Chairman & Chief Executive Officer by Ithaka Acquisition Corp., Managing Director by Tiger Management LLC and Morgan Stanley & Co., Inc., Venture Partner by MPM Capital LP, and Principal by Morgan Stanley Japan Ltd. He also served on the board at WebMD Health Corp., GMP Cos., Inc., Emdeon Corp., HLTH Corp., Manning & Napier, Inc., MPM BioEquities Adviser LLC, Novirio Pharmaceuticals, Inc., TransForm Pharmaceuticals, Inc., and WebMD, Inc. Mr. Brooke received his BA, Cum Laude, from Columbia College and MA from Columbia University.
Paul A. Friedman Currently, Paul A. Friedman is Chairman, President & Chief Executive Officer of Madrigal Pharmaceuticals, Inc. He is also on the board of Incyte Corp. (former President, Chief Executive Officer & Director), Alexion Pharmaceuticals, Inc. and Gliknik, Inc. and Member of American Society for Pharmacology & Experimental Therapeutic, Member of American Society for Biochemistry & Molecular Biology, Inc. and Member of American Society for Clinical Investigation. He previously held the position of Director at Cerulean Pharma, Inc., President of DuPont Pharmaceuticals Research Laboratories, President-Research & Development at DuPont Merck Pharmaceutical Co., Senior Vice President of Merck Research Laboratories and Associate Professor at Harvard Medical School. Paul A. Friedman received an undergraduate degree from Princeton University and a doctorate from Harvard Medical School.
Paula J. Swain Paula J. Swain occupies the position of Executive Vice President-Human Resources for Incyte Corp. Ms. Swain is also on the board of Wilmington Renaissance Corp. and Delaware BioScience Association. In the past she occupied the position of Senior Vice President-Human Resources at Bristol-Myers Squibb Co. and Senior Vice President-Human Resources at DuPont Pharmaceuticals Co. (a subsidiary of Bristol-Myers Squibb Co.). Paula J. Swain received an undergraduate degree from Rockhurst University and an undergraduate degree from Harvard Business School.
Lothar H. Finke Lothar H. Finke is Head-Clinical Development & General Manager-Japan at Incyte Corp. In the past he was Chief Medical Officer at Argos Therapeutics, Inc., Principal at Merck KGaA Principal at Lexigen Pharmaceuticals Corp. and Principal at EMD Pharmaceuticals, Inc. (both are subsidiaries of Merck KGaA) and Principal at Basel Institute for Immunology. He received a doctorate from Philipps University of Marburg.
Jacqualyn A. Fouse Jacqualyn A. Fouse is an American businessperson who has been at the head of 5 different companies. Currently, Dr. Fouse is Chief Executive Officer & Director at Agios Pharmaceuticals, Inc. Dr. Fouse is also on the board of Incyte Corp. and Dick's Sporting Goods, Inc. In the past she was Executive Chairman of Roivant Sciences GmbH, President, Chief Operating Officer & Director at Celgene Corp., Chief Financial Officer of Bunge Ltd., Senior VP, Chief Financial & Strategy Officer at Alcon, Inc. and Chief Financial Officer & SVP-Corporate Strategy at Alcon Laboratories, Inc. (a subsidiary of Alcon, Inc.), Group Treasurer at Nestl�0�1�0�8 SA, Executive Chairman for Axovant Gene Therapies Ltd., Executive Chairman for Dermavant Sciences, Inc., Chief Financial Officer for Swissair Group, Principal at LTV Aerospace & Defense Co. and Principal at Celanese Chemicals, Inc. Dr. Fouse received a graduate degree, a doctorate and an undergraduate degree from The University of Texas at Arlington.
Michael Charles A. Booth Presently, Michael Charles A. Booth occupies the position of Vice President-Investor Relations at Incyte Corp. In his past career he was Member-Management Board at Trout International LLC, Research Analyst at Canaccord Adams Ltd. and Senior VP-Communications & Corporate Affairs at Algeta ASA. He received an undergraduate degree from the University of St. Andrews and a doctorate from the University of Oxford.
Paul J. Clancy Presently, Paul J. Clancy occupies the position of Chief Financial Officer & Executive Vice President of Alexion Pharmaceuticals, Inc., President & Director at Bioverativ Therapeutics, Inc. and Secretary, Director & Vice President at Stromedix, Inc. Mr. Clancy is also on the board of Incyte Corp. and Agios Pharmaceuticals, Inc. Paul J. Clancy previously was Chief Financial Officer & Executive Vice President for Biogen, Inc. Chief Financial Officer & Executive Vice President at Biogen Idec New Ventures, Inc. and Chief Financial Officer of Biogen Idec, Inc. (North Carolina) (both are subsidiaries of Biogen, Inc.) and VP & General Manager-Great West Business Unit at PepsiCo, Inc. Mr. Clancy received an undergraduate degree from Babson College and an MBA from Columbia Business School.
Wendy L. Dixon Wendy L. Dixon is Chairman at Sesen Bio, Inc. and President for Great Meadow Consulting LLC. She is also on the board of 5 other companies. In the past she held the position of Principal at West Pharmaceutical Services, Inc., Senior Vice President & President-Marketing at Merck & Co., Inc., Chief Marketing Officer for Bristol-Myers Squibb Co., Principal at Centocor, Inc., Senior Advisor at The Monitor Group, Inc., Principal at Osteotech, Inc. and Principal at Smithkline & French Laboratories US, Inc. Wendy L. Dixon received a graduate degree, a doctorate and an undergraduate degree from the University of Cambridge.
Reid M. Huber Currently, Reid M. Huber is Chief Scientific Officer & Executive VP at Incyte Corp. He is also on the board of Bellicum Pharmaceuticals, Inc. He previously held the position of Principal Research Scientist at DuPont Pharmaceuticals Co. He received an undergraduate degree from Murray State University (Kentucky) and a doctorate from the University of Washington.
Wenqing Yao Wenqing Yao is Executive Vice President-Discovery Chemistry at Incyte Corp. He previously occupied the position of Principal Scientist at Bristol-Myers Squibb Co. and Principal Scientist at DuPont Pharmaceuticals Co. (a subsidiary of Bristol-Myers Squibb Co.). Dr. Yao received an undergraduate degree from Xuzhou Normal University, a graduate degree from Nankai University and a doctorate from the University of Pennsylvania.
Robert Newton Robert Newton is Vice President-Drug Discovery Biology at Incyte Corp.
Kim Solomon Kim Solomon is Vice President-Project Management at Incyte Corp.
Herv�0�1�0�8 Hoppenot Presently, Herv�0�1�0�8 Hoppenot is Chairman, President & Chief Executive Officer at Incyte Corp. Mr. Hoppenot is also on the board of Biotechnology Innovation Organization, Cellectis SA and Pharmaceutical Research & Manufacturers of America. Mr. Hoppenot previously occupied the position of President for Novartis Oncology, Inc., President of Novartis Pharmaceuticals Corp., Head-US Oncology Business Unit at Aventis SA, Vice President-Oncology Division at Aventis Pharmaceuticals, Inc., Principal at Rhone Poulenc AG, Inc., Head-Product Strategy & Scientific Development at Novartis Pharmaceuticals Corp. and Head-US Oncology Business Unit at Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Keith Mikkelson Keith Mikkelson is Executive Director-Business Development at Incyte Corp.
Steven H. Stein Presently, Steven H. Stein is Chief Medical Officer & Executive Vice President at Incyte Corp. He is also on the board of Kura Oncology, Inc. In the past he was Vice President-Global Oncology at GlaxoSmithKline (New Jersey), Senior VP-US Clinical Development & Medical Affair at Novartis Pharmaceuticals Corp. and SVP-US Clinical Development & Medical Affairs at Novartis Oncology, Inc. Dr. Stein received a doctorate from the University of the Witwatersrand.
Holly Koblish Holly Koblish is Associate Director at Incyte Corp.
Phillip Liu Phillip Liu is Associate Director-Applied Technology at Incyte Corp.
Paul Trower Paul Trower is Vice President-Finance at Incyte Corp. Mr. Trower received an undergraduate degree from Drexel University.
Vijay Iyengar Vijay Iyengar holds the position of President of HistoRx, Inc. Dr. Iyengar is also EVP-Global Strategy & Corporate Development at Incyte Corp. In the past he occupied the position of Engagement Manager at McKinsey & Co., Inc., President at Genoptix, Inc., Global Brand Director-Oncology at Novartis Pharmaceuticals Corp., Vice President & General Manager at Novartis Hellas SACI and Vice President at Novartis Oncology, Inc. Dr. Iyengar received an undergraduate degree from Stanford University and a doctorate from Harvard Medical School.
Michael Morrissey Michael Morrissey is Senior VP & Head-Global Technical Operations at Incyte Corp. In the past he held the position of Vice President & Head-Technical Operations at Celgene International, Inc.
Maria E. Pasquale Presently, Maria E. Pasquale holds the position of Secretary, Executive VP & General Counsel of Incyte Corp. She previously held the position of Chief Counsel & Global Chief Compliance Officer at Celgene Corp. Ms. Pasquale received a graduate degree from Brooklyn Law School and an undergraduate degree from Stony Brook University.
Peter Langmuir Peter Langmuir is Vice President-Oncology Drug Development at Incyte Corp.
Dashyant Dhanak Dashyant Dhanak holds the position of Chief Scientific Officer & Executive VP at Incyte Corp. Dr. Dhanak previously occupied the position of Vice President & Head-Discovery Sciences at Janssen Research & Development LLC and Vice President at GlaxoSmithKline LLC. Dr. Dhanak received an undergraduate degree from the University of Manchester Institute of Science & Technology and a doctorate from the University of London.

量化对比

全部评论 1

  • 【礼来制药公布新冠肺炎治疗方式试验数据 股价涨2.5%】礼来制药股价涨幅扩大至将近2.5%,逼近美股盘初录得的日高153.77美元。礼来制药与Incyte递交新版新冠肺炎病毒治疗药物的(临床)试验数据,礼来制药称,Baricitinib已经改善了治疗效果。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐